Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LBM415

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

NVP PDF 713

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
LBM415 is an antibacterial agent belonging to the peptide deformylase inhibitor class of compounds. It has previously been shown… Expand
Is this relevant?
2009
2009
Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
The intrinsic resistance of P. aeruginosa PAO1 to the peptide deformylase inhibitor (PDF-I) LBM415 was mediated by the MexAB-OprM… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2007
2007
Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number.
Previous genetic analysis of Haemophilus influenzae revealed two mechanisms associated with decreased susceptibility to the novel… Expand
Is this relevant?
2006
2006
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
OBJECTIVES To evaluate the spectrum of activity and potency of LBM415, the first of the peptide deformylase inhibitor (PDFI… Expand
  • table 1
  • table 2
  • table 2
  • table 2
  • table 3
Is this relevant?
2005
2005
Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.
Haemophilus influenzae isolates vary widely in their susceptibilities to the peptide deformylase inhibitor LBM415 (MIC range, 0… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2005
2005
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
LBM415 (NVP PDF-713) is the first member of the peptide deformylase (PDF) inhibitor class being developed for clinical trials as… Expand
  • figure 1
  • table 1
  • table 2
  • table 4
  • table 3
Is this relevant?
2005
2005
Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.
Mycoplasma pneumoniae is a major cause of community-acquired pneumonia. We evaluated the efficacy of LBM415, a novel peptide… Expand
Is this relevant?
2005
2005
In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila.
LBM415 activity against extracellular and intracellular Legionella pneumophila was studied. The LBM415 MIC50 for 20 Legionella sp… Expand
  • figure 1
  • table 1
Is this relevant?
2004
2004
Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
The MICs of LBM415, a new peptide diformylase inhibitor, were evaluated and ranged from 0.03 to 4.0 microg/ml for 300 pneumococci… Expand
Is this relevant?
2004
2004
Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
The MICs of LBM415, a new peptide diformylase inhibitor, were </=0.06 to 4.0 microg/ml for 258 isolates of Staphylococcus aureus… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE